未登录

H

Hirotaka Miyashita

Dartmouth Cancer Center

H指数:22

被引数:2,054

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

OX40 transcriptomic expression and its association with immune checkpoints and clinical outcomes

OX40转录组表达及其与免疫检查点和临床结局的关系

Therapeutic Advances in Medical Oncology

IF4.2

2026-07-120

PRE

Orchestration of B and T cells predicts prolonged survival after cancer immune checkpoint inhibitor therapy

B细胞和T细胞的调控预测癌症免疫检查点抑制剂治疗后的长期生存

npj Precision Oncology

IF8

2026-04-280

OAAI

Predicting Skeletal-Related Events in Bone Metastasis from Advanced Breast Cancer Using Machine Learning

Clinical Breast Cancer

IF2.5

2026-01-120

PRE

Inducible T-Cell Co-Stimulator (ICOS) and ICOS Ligand: Dealing With a Two-Faced Cancer Immunoregulatory System

CANCER MEDICINE

IF3.1

2025-12-310

OAAI

CD40 transcriptomic expression patterns across malignancies: implications for clinical trials of CD40 agonists

CD40转录组表达模式在恶性肿瘤中的差异：对CD40激动剂临床试验的启示

Cancer Immunology, Immunotherapy

IF0

2025-11-030

OAAI

B7-H3/CD276: Novel Immune Checkpoint and Jack of All Trades

B7-H3/CD276：新型免疫检查点与多面手

ImmunoTargets and Therapy

IF4.4

2025-09-050

OA

4-1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4-1BB agonists

CANCER COMMUNICATIONS

IF24.9

2024-08-040

OAAI

KRAS G12C inhibitor combination therapies: current evidence and challenge

KRAS G12C抑制剂联合治疗: 当前证据和挑战

FRONTIERS IN ONCOLOGY

IF3.3

2024-05-0218

OAAI

Viewing the immune checkpoint VISTA: landscape and outcomes across cancers

IF8.3

2024-04-015

OAAI

OX40/OX40 ligand and its role in precision immune oncology

CANCER AND METASTASIS REVIEWS

IF8.7

2024-03-255

OAAI

The predictive role of TNF-related genes in patients receiving immune checkpoint inhibitors

CANCER RESEARCH

IF16.6

2024-03-221

PRE

Genomic and clinical characteristics of advanced pancreatobiliary cancer, stratified by KRAS mutation status

CANCER RESEARCH

IF16.6

2024-03-220

PRE

High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2024-01-064

OAAI

The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer types

AMERICAN JOURNAL OF CANCER RESEARCH

IF2.9

2024-01-012

OA

Pan-cancer analysis of 4-1BB transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors

ANNALS OF ONCOLOGY

IF65.4

2023-11-010

PRE

Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy

MOLECULAR CANCER THERAPEUTICS

IF5.5

2023-08-245

OA

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

npj Genomic Medicine

IF4.8

2023-08-080

OAAI

Correlation among actionable gene mutations, microsatellite instability and tumor mutational burden in advanced colorectal cancer and association with survival

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Clinical usefulness of a novel classification of T cell distribution patterns in the tumor microenvironment of follicular lymphoma to detect transformation

滤泡性淋巴瘤肿瘤微环境中T细胞分布模式的新分类检测转化的临床实用性

ANNALS OF HEMATOLOGY

IF2.4

2022-09-071

PRE

Pan-cancer T-cell priming transcriptomic markers reveals interpatient immunomic heterogeneity independent of histologic type

ANNALS OF ONCOLOGY

IF65.4

2021-09-010

OA